About this trial
The present study will investigate the long term effect of allergen immunotherapy in a real-life study in children with allergy undergoing subcutaneous or sublingual immunotherapy with grass pollen, birch, house dust mites or venom.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Children with moderate to severe allergy to grass pollen, birch, house dust mites or venom who are prescribed allergen immunotherapy
Trial design
Cohort
Prospective
Treatments tested in this trial
Allergen Immunotherapy Extract
DrugPatients will be treated as usual. The study is an observation of the long term effect of the treatment
Treatment groups
Trial outcomes
Primary outcomes
Effect of immunotherapy 5 years after end of treatment
Medication use for allergy and asthma and the patient's experience of effect of the AIT on a scale from 0-4 (0= no effect, 1= modest effect, 2= some effect, 3= good effect, 4= very good effect)
Secondary outcomes
Effect of immunotherapy 10 years after end of treatment
Medication use for allergy and asthma and the patient's experience of effect of the AIT on a scale from 0-4 (0= no effect, 1= modest effect, 2= some effect, 3= good effect, 4= very good effect)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.